BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 15, 2011
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Arena preclinical data

Arena and partner Eisai Co. Ltd. (Tokyo:4523; Osaka:4523, Tokyo, Japan) reported data from a re-adjudication of female rat mammary tumor diagnoses for lorcaserin in a 2-year carcinogenicity study showing that the percentage of malignant tumors was lower for all dose groups of the obesity candidate than in the initial report included in Arena's 2009 NDA. The companies hope the data will address FDA's concerns about an increased rate of mammary tumors in female rats exposed to the serotonin (5-HT2C) receptor agonist. FDA raised...

Read the full 412 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >